• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Tesh Khullar: Reimbursement for Biosimilars

Video

Tesh Khullar, senior vice president and advisor, Flatiron Health, discusses challenges with reimbursement for biosimilars in community oncology practices.

Transcript

We're seeing, and Amgen was the first one to do it, where they went right to the payer. They went to UnitedHealthcare and made sure that their not only branded Neulasta but their biosimilars are on preferred therapy for UnitedHealthcare, which then dictated down to practices needing to utilize it for United Healthcare patients.

So what you're going to see, in our opinion, are biosimilar manufacturers going to payers, getting them on formulary. It's actually going to be a big problem for community oncology. From a financial perspective, it's going to be an opportunity, but the logistical problems of having the brand of biosimilar different by payer is going to be an operational nightmare to manage.

Recent Videos
Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health.
Elena Wolff-Holz, MD.
Elena Wolff-Holz, MD, global head of clinical development at Biocon Biologics
Elena Wolff-Holz, MD
Travis Brewer, Texas Oncology
Josh Canavan, PharmD, head of pharmacy at RazorMetrics
Tiago Biachi, MD, PhD
Elie Bahou, MD, PhD
Steve Pickette, PharmD
Sophia Humphreys, PharmD
Related Content
© 2025 MJH Life Sciences

All rights reserved.